Lasmiditan

(Reyvow®)

Reyvow®

Drug updated on 9/4/2024

Dosage FormTablet (oral; 50 mg, 100 mg)
Drug ClassSerotonin (5-HT) 1F receptor agonists
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the acute treatment of migraine with or without aura in adults.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • Reyvow (lasmiditan) is indicated for the acute treatment of migraine with or without aura in adults.
  • This summary is based on the review of 15 systematic review(s)/meta-analysis(es). [1-15]
  • Lasmiditan (100 mg and 200 mg) was more effective in achieving pain relief within 2 hours compared to ubrogepant (25 mg and 50 mg) and zavegepant. Lasmiditan 200 mg showed a higher rate of pain freedom at 2 hours than lasmiditan 100 mg.
  • For sustained pain relief over 24 hours, rimegepant (75 mg) and ubrogepant (50 mg and 100 mg) were more effective than zavegepant. Lasmiditan 200 mg also provided better sustained pain freedom compared to lasmiditan 100 mg.
  • Rimegepant (75 mg) had a higher likelihood of achieving freedom from photophobia within 2 hours compared to ubrogepant (25 mg) and lasmiditan (50 mg). Lasmiditan (100 mg and 200 mg) and rimegepant were equally effective in achieving two-hour freedom from the most bothersome symptom.
  • Lasmiditan (100 mg and 200 mg) showed higher efficacy in pain freedom at 2 hours compared to rimegepant (75 mg) and ubrogepant (25 mg and 50 mg), with triptans demonstrating even higher odds ratios for pain freedom at 2 hours compared to lasmiditan, rimegepant, and ubrogepant.
  • Adverse events: Lasmiditan exhibited the highest risk of adverse events, including dizziness (RR up to 12.77), somnolence, asthenia, paresthesia, and fatigue, with a higher incidence observed in the 200 mg group compared to the 100 mg group.
  • Comparison to other drugs: Rimegepant and ubrogepant had lower rates of adverse events compared to lasmiditan, which also had a higher incidence of central nervous system-related side effects compared to placebo and other drugs.
  • Subgroup considerations: In patients with cardiovascular risk factors, lasmiditan 200 mg was associated with a higher risk of adverse events compared to 100 mg.
  • There is no population type or subgroup information available in the reviewed studies.

Product Monograph / Prescribing Information

Document TitleYearSource
Reyvow (lasmiditan) Prescribing Information.2022Lilly USA, LLC., Indianapolis, IN

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Comparison of effectiveness and safety of lasmiditan and CGRP-antagonists for the acute treatment of migraine in adults: systematic review and network meta-analysis of randomised trials. 2024The Journal of Headache and Pain
Comparison of lasmiditan 200 mg versus 100 mg for migraine patients: a meta-analysis of randomized controlled studies. 2024Clinical Neuropharmacology
Exploration of lasmiditan 200 mg versus 100 mg for the treatment of migraine: a meta-analysis based on aggregate data. 2024Clinical Neuropharmacology
Efficacy, safety and indirect comparisons of lasmiditan, rimegepant, and ubrogepant for the acute treatment of migraine: a systematic review and network meta-analysis of the literature.2023Cephalalgia
Rimegepant, ubrogepant, and lasmiditan in the acute treatment of migraine examining the benefit-risk profile using number needed to treat/harm.2022The Clinical Journal of Pain
Relative efficacy of lasmiditan versus rimegepant and ubrogepant as acute treatments for migraine: network meta-analysis findings.2022The Journal of Headache and Pain
Lasmiditan abortive therapy for episodic migraine in phase II/III randomized clinical trials: a meta-analysis.2022Indian Journal of Pharmacology
Efficacy and safety of lasmiditan for acute treatment of migraine in adults: a meta-analysis.2021The Journal of Clinical Pharmacology
The effect and safety of 5-HT1F receptor agonist lasmiditan on migraine: a systematic review and meta-analysis.2021BioMed Research International
Acute treatments for episodic migraine in adults: a systematic review and meta-analysis.2021JAMA
Comparison of new pharmacologic agents with triptans for treatment of migraine: a systematic review and meta-analysis.2021JAMA
Optimal dosing of lasmiditan in the management of acute migraine attack: a systematic review and meta-analysis.2021Annals of Indian Academy of Neurology
Comparative efficacy and safety of rimegepant, ubrogepant, and lasmiditan for acute treatment of migraine: a network meta-analysis.2021Expert Review of Pharmacoeconomics & Outcomes Research
Lasmiditan for acute treatment of migraine in adults: a systematic review and meta-analysis of randomized controlled trials.2020CNS Drugs
Short-term efficacy and safety of lasmiditan, a novel 5-HT1F receptor agonist, for the acute treatment of migraine: a systematic review and meta-analysis.2020The Journal of Headache and Pain

Clinical Practice Guidelines